Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NEK2 | P51955 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659196 | 0.76 | MAOB (0.57) | HTTKDM4EPOLBNEK2MAOB | |
| SCHEMBL2659198 | 0.76 | MAOB (0.57) | HTTKDM4EPOLBNEK2MAOB | |
| SCHEMBL21519402 | 0.74 | HTT (1.00) | LMNAHTTKDM4EPOLBMAOB | |
| SCHEMBL28868030 | 0.74 | KDM4E (1.00) | LMNAKDM4EPOLBMAOB | |
| Cyanide SCHEMBL22130314 | 0.73 | MAOB (0.53) | KDM4EPOLBNEK2MAOBRAB9A | |
| SCHEMBL1754870 | 0.72 | NEK2 (0.62) | KDM4EPOLBNEK2MAOBRAB9A | |
| SCHEMBL12675994 | 0.71 | NEK2 (0.69) | KDM4EPOLBNEK2MAOBRAB9A | |
| SCHEMBL6599321 | 0.71 | ROCK2 (0.53) | KDM4EPOLBNEK2MAOBRAB9A | |
| SCHEMBL5823137 | 0.71 | ROCK2 (0.63) | KDM4EPOLBMAOBRAB9A | |
| SCHEMBL12858839 | 0.70 | KDM4E (0.70) | LMNAHTTKDM4EPOLBMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970456-B1 | Synthesis of thiosemicarbazide analogue as inhibitor of tyrosinase, skin hyperpigmentation, and fruit and/or vegetable browning | KING SAUD UNIVERSITY (SA) | 2024-04-30 | — | — | US | claimed |
| US-11970456-B1 | Synthesis of thiosemicarbazide analogue as inhibitor of tyrosinase, skin hyperpigmentation, and fruit and/or vegetable browning | KING SAUD UNIVERSITY (SA) | 2024-04-30 | — | — | US | disclosed |
| US-11970456-B1 | Synthesis of thiosemicarbazide analogue as inhibitor of tyrosinase, skin hyperpigmentation, and fruit and/or vegetable browning | KING SAUD UNIVERSITY (SA) | 2024-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970456-B1 | Synthesis of thiosemicarbazide analogue as inhibitor of tyrosinase, skin hyperpigmentation, and fruit and/or vegetable browning | TYR, TH, PRKACA | LMNA 4834/4885HTT 908/4885KDM4E 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.